PHARMACOKINETICS AND TOLERANCE OF ENOXACIN IN HEALTHY-VOLUNTEERS ADMINISTERED AT A DOSAGE OF 400-MG TWICE DAILY FOR 14 DAYS

被引：18

作者：

TSUEI, SE ^{[1
]}

DARRAGH, AS ^{[1
]}

BRICK, I ^{[1
]}

机构：

[1] ST JAMES HOSP,INST CLIN PHARMACOL,DUBLIN,IRELAND

来源：

关键词：

D O I：

10.1093/jac/14.suppl_C.71

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：71 / 74

页数：4

共 6 条

[1] INVITRO ACTIVITY OF CI-919 (AT-2266), AN ORAL ANTI-PSEUDONOMAL COMPOUND
CHARTRAND, SA
SCRIBNER, RK
WEBER, AH
WELCH, DF
MARKS, MI
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (05) : 658 - 663
[2] INVITRO AND INVIVO ANTI-BACTERIAL ACTIVITY OF AT-2266
KOUNO, K
INOUE, M
MITSUHASHI, S
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (01) : 78 - 84
[3] MATSUMOTO JI, 1980, CURRENT CHEMOTHERAPY, P454
[4] DETERMINATION OF A NEW ANTIBACTERIAL AGENT (AT-2266) AND ITS METABOLITES IN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
NAKAMURA, R
YAMAGUCHI, T
SEKINE, Y
HASHIMOTO, M
[J]. JOURNAL OF CHROMATOGRAPHY, 1983, 278 (02): : 321 - 328
[5] NAKAMURA S, 1980, CURRENT CHEMOTHERAPY, P456
[6] [No title captured]